scholarly journals Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: The baltimore longitudinal study of aging

2010 ◽  
Vol 14 (7) ◽  
pp. 507-513 ◽  
Author(s):  
Richard D. Semba ◽  
J. Beck ◽  
K. Sun ◽  
J. M. Egan ◽  
O. D. Carlson ◽  
...  
Keyword(s):  
Longitudinal Study ◽  
Glucose Metabolism ◽  
Advanced Glycation ◽  
Advanced Glycation End Product ◽  
Abnormal Glucose Metabolism ◽  
Carboxymethyl Lysine ◽  
Baltimore Longitudinal Study ◽  
Relationship Of

scholarly journals Relationship of Serum Fibroblast Growth Factor 21 with Abnormal Glucose Metabolism and Insulin Resistance: The Baltimore Longitudinal Study of Aging

2012 ◽  
Vol 97 (4) ◽  
pp. 1375-1382 ◽  
Author(s):  
Richard D. Semba ◽  
Kai Sun ◽  
Josephine M. Egan ◽  
Candace Crasto ◽  
Olga D. Carlson ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Glucose Metabolism ◽  
Plasma Glucose ◽  
Community Dwelling ◽  
Fibroblast Growth Factor 21 ◽  
Abnormal Glucose Metabolism ◽  
Matsuda Index ◽  
Baltimore Longitudinal Study ◽  
Relationship Of ◽  
The Relationship

Context: The relationship of fibroblast growth factor 21 (FGF21) with glucose metabolism and insulin resistance has not been well characterized in community-dwelling adults. Objective: The objective of the study was to examine the relationship of FGF21 with glucose metabolism and insulin resistance. Design: Serum FGF21, fasting plasma glucose (FPG), glucose tolerance, and insulin resistance were measured in a cross-sectional study, 2002–2007. Setting: The study was the Baltimore Longitudinal Study of Aging, a natural history cohort study of aging in community-dwelling men and women. Participants: Seven hundred adults, mean age 63.3 yr, participated in the study. Main Outcome Measures: FPG, 2-h plasma glucose, homeostasis model of insulin resistance, whole-body insulin sensitivity (Matsuda index), glucose area under the curve (AUC), and insulin AUC were measured. Results: Overall, the median (25th and 75th percentiles) FGF21 concentration was 225 (126, 370) pg/ml. The proportion of adults with normal, impaired, and diabetic FPG was 77.0, 21.4, and 1.6%, and those with normal, impaired, and diabetic 2-h plasma glucose was 76.7, 19.1, and 4.1%, respectively. Log serum FGF21 (picograms per milliliter), per 1 sd increase, was associated with an FPG (odds ratio 1.43, 95% confidence interval 1.15, 1.77, P = 0.001) and with 2-h plasma glucose (odds ratio 1.39, 95% confidence interval 1.12, 1.73, P = 0.003), in respective multivariate, ordered logistic regression models, adjusted for potential confounders. Serum FGF21 (picograms per milliliter) was associated with the homeostasis model of insulin resistance, the Matsuda index, glucose AUC, and insulin AUC (all P < 0.0001) in respective multivariable linear regression models adjusted for potential confounders. Conclusions: Higher serum FGF21 concentrations were associated with abnormal glucose metabolism and insulin resistance in community-dwelling adults.

An inhibitor of advanced glycation end product formation reducesNϵ-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats

2003 ◽  
Vol 41 (3) ◽  
pp. S68-S71 ◽  
Author(s):  
Sakurako Nakamura ◽  
Tetsuya Tachikawa ◽  
Kazuki Tobita ◽  
Isao Aoyama ◽  
Fumio Takayama ◽  
...  
Keyword(s):  
Product Formation ◽  
Diabetic Rats ◽  
Advanced Glycation ◽  
Advanced Glycation End Product ◽  
Carboxymethyl Lysine

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes

Diabetes Care ◽  
1998 ◽  
Vol 21 (11) ◽  
pp. 1997-2002 ◽  
Author(s):  
T. J. Berg ◽  
J. T. Clausen ◽  
P. A. Torjesen ◽  
K. Dahl-Jorgensen ◽  
H. J. Bangstad ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Advanced Glycation ◽  
Advanced Glycation End Product ◽  
Carboxymethyl Lysine

scholarly journals Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study

2016 ◽  
Vol 13 (4) ◽  
pp. 278-285 ◽  
Author(s):  
Pauline BC Linssen ◽  
Ronald MA Henry ◽  
Casper G Schalkwijk ◽  
Jacqueline M Dekker ◽  
Giel Nijpels ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glucose Metabolism ◽  
Advanced Glycation Endproducts ◽  
Left Ventricular ◽  
Advanced Glycation ◽  
Glycation Endproducts ◽  
Normal Glucose ◽  
Carboxymethyl Lysine

Objective: To investigate whether serum advanced glycation endproducts are associated with left ventricular systolic and diastolic function in participants with normal glucose metabolism, impaired glucose metabolism and type 2 diabetes mellitus. Methods: Participants from a cross-sectional, population-based study ( n = 280 with normal glucose metabolism, n = 171 with impaired glucose metabolism, n = 242 with type 2 diabetes mellitus) underwent echocardiography. Serum protein-bound advanced glycation endproducts [i.e. Nε-(carboxymethyl)lysine, pentosidine and Nε-(carboxyethyl)lysine] were measured. Linear regression analyses were used and stratified according to glucose metabolism status. Results: In normal glucose metabolism, higher Nε-(carboxymethyl)lysine and pentosidine levels were associated with worse diastolic function (left atrial volume index and left atrial volume × left ventricular mass index product term) and higher Nε-(carboxymethyl)lysine and Nε-(carboxyethyl)lysine levels with worse systolic function (ejection fraction). In impaired glucose metabolism, a similar pattern emerged, though less consistent. In type 2 diabetes mellitus, these associations were non-existent for diastolic function or even reversed for systolic function. Conclusion: This suggests that serum advanced glycation endproducts are associated with impaired left ventricular function in normal glucose metabolism, but that with deteriorating glucose metabolism status, serum advanced glycation endproducts may not mirror heart failure risk.

Sign in / Sign up

Export Citation Format

Share Document